Elicio Therapeutics, Inc. (ELTX) Income Statement
ELTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsELTX revenue and net income
ELTX profit margins
ELTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ELTX quarterly EPS vs estimates
Elicio Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.42).
ELTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $28.3M | $2.9M | $1.5M | $4.0M | $6.6M | $7.3M |
| Cost of revenue | $1.1M | $1.2M | $1.2M | $1.1M | $1.2M | $1.8M | $1.1M | $380,000 | $3.2M | $3.7M |
| Gross profit | −$1.1M | −$1.2M | −$1.2M | −$1.1M | $27.1M | $1.1M | $351,000 | $3.6M | $3.4M | $3.6M |
| Research & development | $24.9M | $33.7M | $22.7M | $17.0M | $48.6M | $38.9M | $29.8M | $9.2M | $196,008 | — |
| Sales, general & admin | $12.8M | $11.3M | $11.9M | $5.6M | $7.5M | $3.0M | $2.8M | — | — | — |
| Total operating expenses | $36.6M | $43.8M | $34.6M | $22.7M | $66.4M | $56.3M | $38.9M | $18.0M | $3.8M | $4.0M |
| Operating income | −$37.7M | −$45.0M | −$35.7M | −$23.7M | −$39.3M | −$55.3M | −$38.6M | −$14.3M | −$397,800 | −$419,220 |
| Interest income | $776,000 | $777,000 | $373,000 | $64,829 | $3,392 | $8,942 | $81,481 | — | — | — |
| Interest expense | $1.1M | $455,000 | $1.1M | $3.6M | $876,442 | $8.8M | — | — | $300,432 | $307,450 |
| Income before taxes | −$39.6M | −$51.9M | −$35.2M | −$28.2M | −$54.6M | −$80.1M | −$40.7M | −$20.0M | $1.7M | $1.2M |
| Income taxes | — | — | — | $3.6M | $876,442 | $8,942 | $81,481 | — | $452,778 | $201,858 |
| Net income | −$39.6M | −$51.9M | −$35.2M | −$28.2M | −$26.4M | −$80.1M | −$40.7M | −$20.0M | $632,241 | $307,303 |
| EBITDA | −$37.3M | −$50.3M | −$33.0M | −$23.6M | −$51.9M | −$70.6M | −$40.2M | −$14.3M | $62,540 | $2.0M |
| EPS (diluted) | −$2.62 | −$4.20 | −$6.96 | −$34.26 | −$8.81 | −$10.73 | −$13.79 | — | — | — |
| Gross margin | — | — | — | — | 95.6% | 36.9% | 23.6% | 90.6% | 51.8% | 49.7% |
| Operating margin | — | — | — | — | −138.8% | −1,919.2% | −2,595.2% | −356.0% | −6.0% | −5.7% |
| Net margin | — | — | — | — | −93.2% | −2,781.5% | −2,734.2% | −497.0% | 9.6% | 4.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.2M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $289,000 | $286,000 | $283,000 | $281,000 | $278,000 | $305,000 | $290,000 | $293,000 | $290,000 | $286,000 | — |
| Gross profit | — | −$289,000 | −$286,000 | −$283,000 | −$281,000 | −$278,000 | −$305,000 | −$290,000 | −$293,000 | −$290,000 | −$286,000 | — |
| Research & development | $6.8M | $6.7M | $5.1M | $5.0M | $7.0M | $7.8M | $10.6M | $7.2M | $8.2M | $7.6M | $6.2M | $7.3M |
| Sales, general & admin | $3.6M | $3.8M | $3.8M | $3.0M | $3.1M | $3.0M | $2.8M | $3.1M | $2.7M | $2.7M | $3.2M | $3.5M |
| Total operating expenses | $10.4M | $10.3M | $8.8M | $8.0M | $10.1M | $10.5M | $13.2M | $10.1M | $10.6M | $10.0M | $9.1M | $10.8M |
| Operating income | −$10.4M | −$10.6M | −$8.8M | −$8.0M | −$10.1M | −$10.7M | −$13.5M | −$10.3M | −$10.9M | −$10.2M | −$9.4M | −$10.8M |
| Interest income | $138,000 | $157,000 | $199,000 | $199,000 | $168,000 | $210,000 | $305,000 | $185,000 | $137,000 | $150,000 | $75,000 | $246,000 |
| Interest expense | $410,000 | $407,000 | $337,000 | $426,000 | $194,000 | $176,000 | $234,000 | $137,000 | $49,000 | $36,000 | $2,000 | $1,000 |
| Income before taxes | −$8.2M | −$11.8M | −$7.7M | −$10.1M | −$10.6M | −$11.2M | −$14.0M | −$18.8M | −$7.2M | −$11.8M | −$8.9M | −$10.7M |
| Income taxes | — | — | — | — | — | — | −$36,000 | — | — | $36,000 | $2,000 | −$273,000 |
| Net income | −$8.2M | −$11.8M | −$7.7M | −$10.1M | −$10.6M | −$11.2M | −$14.0M | −$18.8M | −$7.2M | −$11.8M | −$8.9M | −$10.7M |
| EBITDA | −$12.6M | −$11.1M | −$7.1M | −$9.4M | −$10.1M | −$10.8M | −$13.5M | −$18.4M | −$6.9M | −$11.5M | −$8.7M | −$10.4M |
| EPS (diluted) | −$0.43 | −$0.65 | −$0.49 | −$0.60 | −$0.66 | −$0.87 | −$1.02 | −$1.39 | −$0.64 | −$1.15 | −$1.75 | −$1.27 |
| Gross margin | — | — | — | — | — | — | −26.2% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −1,155.7% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −1,201.0% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ELTX's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ELTX financial results
Elicio Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $39.6 million. Diluted earnings per share came to −$2.62.
See the ELTX stock overview for the latest quote and news, or the ELTX chart for price history and technical indicators.
ELTX income statement FAQ
Does Elicio Therapeutics have revenue?
Elicio Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Elicio Therapeutics profitable?
No. Elicio Therapeutics reported a net loss of $39.6 million in fiscal 2025.
How much does Elicio Therapeutics spend on research and development?
Elicio Therapeutics spent $24.9 million on research and development in fiscal 2025.
What are Elicio Therapeutics's earnings per share?
Elicio Therapeutics earned $-2.62 per diluted share in fiscal 2025, compared with $-4.20 a year earlier.
When will Elicio Therapeutics report its next earnings?
Elicio Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Elicio Therapeutics's fiscal year end?
Elicio Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.